1072 results
-
List item
News: EMA starts review of VIR-7831 for treating patients with COVID-19 (new)
CHMP, Last updated: 15/04/2021 -
List item
News: AstraZeneca’s COVID-19 vaccine: EMA to provide further context on risk of very rare blood clots with low blood platelets (new)
CHMP, Last updated: 14/04/2021 -
List item
News: COVID-19 Vaccine Janssen: assessment of very rare cases of unusual blood clots with low platelets continues (new)
PRAC, Last updated: 14/04/2021 -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6-9 April 2021 (new)
PRAC, Last updated: 09/04/2021 -
List item
News: AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets (new)
PRAC, Last updated: 07/04/2021 -
List item
Press briefing on the conclusion of the assessment of the Pharmacovigilance Risk Assessment Committee (PRAC) of Vaxzevria (previously COVID-19 Vaccine AstraZeneca) and thromboembolic events (new)
Virtual meeting, 07/04/2021, Last updated: 07/04/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 24-27 January 2022 (new)
European Medicines Agency, Amsterdam, the Netherlands, from 24/01/2022 to 27/01/2022, Last updated: 06/04/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 February 2022 (new)
European Medicines Agency, Amsterdam, the Netherlands, from 21/02/2022 to 24/02/2022, Last updated: 06/04/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 March 2022 (new)
European Medicines Agency, Amsterdam, the Netherlands, from 21/03/2022 to 24/03/2022, Last updated: 06/04/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 April 2022 (new)
European Medicines Agency, Amsterdam, the Netherlands, from 19/04/2022 to 22/04/2022, Last updated: 06/04/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 16-19 May 2022 (new)
European Medicines Agency, Amsterdam, the Netherlands, from 16/05/2022 to 19/05/2022, Last updated: 06/04/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 20-23 June 2022 (new)
European Medicines Agency, Amsterdam, the Netherlands, from 20/06/2022 to 23/06/2022, Last updated: 06/04/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 18-21 July 2022 (new)
European Medicines Agency, Amsterdam, the Netherlands, from 18/07/2022 to 21/07/2022, Last updated: 06/04/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 16-19 August 2022 (new)
Written procedure, from 16/08/2022 to 19/08/2022, Last updated: 06/04/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 12-15 September 2022 (new)
European Medicines Agency, Amsterdam, the Netherlands, from 12/09/2022 to 15/09/2022, Last updated: 06/04/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 10-13 October 2022 (new)
European Medicines Agency, Amsterdam, the Netherlands, from 10/10/2022 to 13/10/2022, Last updated: 06/04/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 7-10 November 2022 (new)
European Medicines Agency, Amsterdam, the Netherlands, from 07/11/2022 to 10/11/2022, Last updated: 06/04/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 12-15 December 2022 (new)
European Medicines Agency, Amsterdam, the Netherlands, from 12/12/2022 to 15/12/2022, Last updated: 06/04/2021 -
List item
News: AstraZeneca COVID-19 vaccine: review of very rare cases of unusual blood clots continues (new)
PRAC, Last updated: 31/03/2021 -
List item
News: Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna (new)
CHMP, Last updated: 26/03/2021 -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 March 2021 (new)
CHMP, Last updated: 26/03/2021 -
List item
News: EMA issues advice on use of regdanvimab for treating COVID-19 (new)
CHMP, Last updated: 26/03/2021 -
List item
News: COVID-19 Vaccine AstraZeneca – Update on ongoing evaluation of blood clot cases (new)
PRAC, Last updated: 25/03/2021 -
List item
News: COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets (updated)
PRAC, Last updated: 19/03/2021 -
List item
Press briefing on the conclusion of the investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events by the Pharmacovigilance Risk Assessment Committee (PRAC) (updated)
Virtual meeting, 18/03/2021, Last updated: 19/03/2021